Plain-English translation of NCT06578104 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This trial is testing the PulseSelect™ PFA System, a device used to treat atrial fibrillation (a condition where your heart beats irregularly). Doctors use this device during a procedure to help restore a normal heart rhythm. The study will follow patients for three years after their procedure to see how well the treatment works and how safe it is.
Atrial fibrillation can cause serious health problems, and medications don't always help everyone. This trial is checking whether this approved ablation device is safe and effective for patients whose symptoms don't respond well to heart rhythm medications.
You likely qualify if…
You likely don't qualify if…
You will receive the ablation procedure as part of your standard care at the hospital. After your procedure, you'll have follow-up visits at 3, 6, 12, 24, and 36 months to check your recovery. At some of these visits, you'll wear a portable heart monitor for 24 hours to help doctors see how your heart rhythm is doing. The entire study lasts three years from your procedure date.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States